semaglutide 7.2 A stronger mg dose of Wegovy wins FDA approval after a 54-day review, promising greater weight loss for eligible patients. See more: https://www.wmar2news.com/health/medicine/fast-track-fda-approval-brings-stronger-wegovy-to-pharmacies-by-april Weekly dose of semaglutide 7.2

Why GLP-1s Matter Significant weight loss benefits Improved glycemic control Cardiovascular risk reduction Growing applications beyond diabetes Potential expansion into liver disease, kidney disease, and other metabolic disorders The GLP-1 story is no longer just about diabetes

Despite decades of research, treatment options are sparse or missing, and relapse rates are high

Consumer-directed health care in a retail health context is a growing force as patients face high deductibles, denials of care, lack of access, now demanding convenience and retail-style omni-channel on-ramps for care, products, support, and I daresay, respect and empathy

And other biotech news stories of the day, brought to you by The Readout.